

Prescribe XPHOZAH With Confidence

 XPHOZAH[®]
(tenapanor) tablets



Identify the appropriate patients

- Decide, based on clinical judgment, which patients should be on XPHOZAH



Write and send XPHOZAH prescriptions to Transition Pharmacy in Trevose, Pennsylvania, the ArdelyxAssist™ specialty pharmacy partner



E-prescribe

Transition Pharmacy
Services, LLC
Trevose, Pennsylvania
NPI #: 1336325265



Call

877-527-3927
Option 1



Fax

877-594-4906

Be sure to include your patient's dialysis center on all prescriptions



Inform patients that they must respond to a call or text from ArdelyxAssist for their prescription to be processed

- Phone calls or text messages are used to confirm consent, affordability, and shipping address
 - **Note:** *The number one cause of delay is patients not answering the pharmacy's call or text*
- If your patient does not respond to the call or text, a Field Access Manager (FAM) will contact the clinical care team to help assist with follow-up
- Expect a call from ArdelyxAssist to discuss prior authorization needs

Helpful Tips to Support Timely Access

- Use the Transition Pharmacy Prescription Form and complete all sections, including patients' lab values, binder history, and dialysis center information
- Submit the Patient Consent Form with the prescription
 - **Note:** *Patients may consent by phone, but submitting the form may help expedite the process*
- Fax all forms to 877-594-4906

Help Your Patients Start XPHOZAH by Sharing This Information With Them

- Stop the use of laxatives and stool softeners. Remind patients to tell their doctor if severe diarrhea occurs
- Do not take XPHOZAH right before a hemodialysis session, as patients may experience diarrhea. Instead, take XPHOZAH right before the next meal following dialysis
- If patients experience diarrhea, it will likely happen soon after starting XPHOZAH but could occur at any time during treatment. Diarrhea typically resolves with continued treatment or their doctor may lower their dose



For all prescriptions, an Ardelyx Field Access Manager (FAM) will contact the clinical care team (nephrologists, RDs, NPs, PAs, or others) to support access needs, such as prior authorization information

If you have any questions, need support with access or affordability, or want program information, please call us at 877-527-3927 and select option 2 or contact your FAM directly

INDICATION

XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

XPHOZAH is contraindicated in:

- Pediatric patients under 6 years of age
- Patients with known or suspected mechanical gastrointestinal obstruction

WARNINGS AND PRECAUTIONS

Diarrhea

Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

MOST COMMON ADVERSE REACTIONS

Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

Please see full Prescribing Information at [XPHOZAH.com/PI](https://www.ardelyx.com/PI).

Reference: 1. XPHOZAH® (tenapanor) full Prescribing Information. Waltham, MA: Ardelyx, Inc.; 2025.



© Ardelyx, Inc. 2025. All rights reserved. Ardelyx and XPHOZAH are registered trademarks of Ardelyx, Inc. and ArdelyxAssist is a trademark of Ardelyx, Inc. US-XPH-0479 07/25

